Last reviewed · How we verify
REP 2139-Mg
At a glance
| Generic name | REP 2139-Mg |
|---|---|
| Also known as | not availalble |
| Sponsor | Replicor Inc. |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Replicor Compassionate Access Program
- REP 2139-Mg and REP 2165-Mg Combination Therapy in Chronic Hepatitis B Infection (PHASE2)
- REP 2139-Ca / Pegasys™ Combination Therapy in Hepatitis B / Hepatitis D Co-infection (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- REP 2139-Mg CI brief — competitive landscape report
- REP 2139-Mg updates RSS · CI watch RSS
- Replicor Inc. portfolio CI